Equity Profile

MEDP

Medpace Holdings, Inc.

Health CareLife Sciences Tools & Services$12.8B

Jul20Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Medpace Holdings, Inc. is a healthcare company that provides clinical research services to the pharmaceutical and biotechnology industries....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its business and capture market share in a competitive industry.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MEDP Q2-2026 Earnings Preview

Context

Company Snapshot

Medpace Holdings, Inc. is a healthcare company that provides clinical research services to the pharmaceutical and biotechnology industries. With a market cap of $13 billion, it plays a crucial role in the life sciences sector, helping to bring new drugs and therapies to market efficiently.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+12.59%

Avg Stock Reaction

-0.46%

Last Quarter Recap

In Q1-2026, Medpace reported an EPS of $4.28, exceeding expectations by 14.53%. However, the stock saw a slight decline of 1.25% the following day, indicating mixed investor sentiment despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Medpace's upcoming earnings, especially given its strong track record of beating EPS estimates. However, the lack of revenue guidance raises concerns about future growth.

Bull Case

If Medpace continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to provide clear guidance or shows signs of slowing revenue growth, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Medpace's history of beating EPS estimates, this figure will be crucial in determining investor sentiment and stock performance.

Will there be any guidance on revenue growth for the upcoming quarters?

Clear revenue guidance is essential for assessing the company's future growth prospects and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Medpace to exceed EPS expectations again, given its strong historical performance.

Supporting Evidence

Medpace has consistently beaten EPS estimates in the past, indicating strong operational execution.

The options market is pricing in a significant move, suggesting that investors are anticipating volatility that could favor a positive outcome.

Key Risk

If the EPS comes in below $4.00, it could challenge the current positive sentiment around the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Medpace's ability to maintain its earnings momentum and provide clarity on future growth.

Bull Confirmed If

An EPS of $4.50 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $4.00 would confirm the bear case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±20.52%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect notable volatility around the earnings report.

Options are pricing ±20.5% while MEDP has averaged ±1.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

80.4%

Calls (2K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Medpace beats expectations and raises guidance, history suggests the stock could see a positive reaction, potentially around a 1.49% increase on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors weigh the implications.

Miss

If the company misses expectations, history suggests a potential decline of around 1.49%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·2 sells

Members

House only

Est. Notional

$18,004.00–$95,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new client contracts or partnerships that could drive revenue growth.
2Insights into the clinical trial success rates and how they compare to industry standards.
3Comments on operational efficiencies and cost management strategies.
4Guidance on revenue expectations for the next quarter and beyond.
5Any commentary on market trends affecting the life sciences sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ICICI Bank Limited

Company Snapshot

Medpace Holdings, Inc. is a healthcare company that provides clinical research services to the pharmaceutical and biotechnology industries....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its business and capture market share in a competitive industry.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MEDP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+12.59%

Avg Stock Reaction

-0.46%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Medpace continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to provide clear guidance or shows signs of slowing revenue growth, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Medpace's history of beating EPS estimates, this figure will be crucial in determining investor sentiment and stock performance.

Will there be any guidance on revenue growth for the upcoming quarters?

Clear revenue guidance is essential for assessing the company's future growth prospects and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Medpace to exceed EPS expectations again, given its strong historical performance.

Supporting Evidence

Medpace has consistently beaten EPS estimates in the past, indicating strong operational execution.

The options market is pricing in a significant move, suggesting that investors are anticipating volatility that could favor a positive outcome.

Key Risk

If the EPS comes in below $4.00, it could challenge the current positive sentiment around the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Medpace's ability to maintain its earnings momentum and provide clarity on future growth.

Bull Confirmed If

An EPS of $4.50 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $4.00 would confirm the bear case, suggesting potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±20.52%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect notable volatility around the earnings report.

Options are pricing ±20.5% while MEDP has averaged ±1.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

80.4%

Calls (2K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Medpace beats expectations and raises guidance, history suggests the stock could see a positive reaction, potentially around a 1.49% increase on the first day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors weigh the implications.

Miss

If the company misses expectations, history suggests a potential decline of around 1.49%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·2 sells

Members

House only

Est. Notional

$18,004.00–$95,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new client contracts or partnerships that could drive revenue growth.
2Insights into the clinical trial success rates and how they compare to industry standards.
3Comments on operational efficiencies and cost management strategies.
4Guidance on revenue expectations for the next quarter and beyond.
5Any commentary on market trends affecting the life sciences sector.